BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Women's Health Product Already Approved by Health Canada-2014 Launch Planned
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 10/01/13 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Canadian Licence and Distribution Agreement with its third European partner for a women's health product that has prior approval from Health Canada.
The product has been widely approved in Europe and is successfully marketed in countries such as Germany, France, Italy, Spain, Sweden, Poland, Austria, and Belgium. "Pre-launch preparations have commenced and we are planning for a first half 2014 launch of this new product," said Rene Goehrum, BioSyent CEO. "It will be a good complement to both our promotion activities for FeraMAX® 150 and our Hospital Products Division."
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit .
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,571,195 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contacts:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.10.2013 - 12:00 Uhr
Sprache: Deutsch
News-ID 301575
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Women's Health Product Already Approved by Health Canada-2014 Launch Planned"
steht unter der journalistisch-redaktionellen Verantwortung von
BioSyent Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
